Edward Nash
Stock Analyst at Canaccord Genuity
(4.39)
# 307
Out of 4,944 analysts
85
Total ratings
50%
Success rate
21.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $420 → $428 | $373.46 | +14.60% | 10 | Aug 6, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $142 → $137 | $72.80 | +88.19% | 8 | Aug 1, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $28 | $9.58 | +192.28% | 1 | Jul 24, 2025 | |
| VRNA Verona Pharma | Downgrades: Hold | $107 | $105.20 | +1.71% | 10 | Jul 9, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $24.99 | +156.10% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $18.05 | +160.39% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.53 | +1,604.55% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.60 | +150.00% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $48.31 | +51.11% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $37.36 | +138.22% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $14 | $2.85 | +391.23% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.11 | +620.72% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $4.02 | +397.51% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $3.23 | +147.68% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $6.47 | +162.75% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.12 | -5.66% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.46 | +12,228.77% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $28.97 | +183.05% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.66 | +2,907.52% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.60 | +228.77% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $6.56 | +9,808.54% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $420 → $428
Current: $373.46
Upside: +14.60%
Corcept Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $142 → $137
Current: $72.80
Upside: +88.19%
Sagimet Biosciences
Jul 24, 2025
Initiates: Buy
Price Target: $28
Current: $9.58
Upside: +192.28%
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $105.20
Upside: +1.71%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $24.99
Upside: +156.10%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $18.05
Upside: +160.39%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.53
Upside: +1,604.55%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.60
Upside: +150.00%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $48.31
Upside: +51.11%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $37.36
Upside: +138.22%
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.85
Upside: +391.23%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.11
Upside: +620.72%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $4.02
Upside: +397.51%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $3.23
Upside: +147.68%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $6.47
Upside: +162.75%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.12
Upside: -5.66%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.46
Upside: +12,228.77%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $28.97
Upside: +183.05%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.66
Upside: +2,907.52%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $14.60
Upside: +228.77%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $6.56
Upside: +9,808.54%